Compare State Street Corporation Common Stock (STT) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street Corporation Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? State Street Corporation Common Stock trades at $167.94 (market cap $47.83B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: State Street Corporation Common Stock is far larger — about 6.4× Spyre Therapeutics Inc. Common Stock's market cap, and State Street Corporation Common Stock pays a 2.11% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold State Street Corporation Common Stock for 2 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| STT | SYRE | |
|---|---|---|
Market Cap | $47.83B | $7.52B |
Volume | 2,907,463 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $194.26 | $108.92 |
52-Week Low | $111.37 | $22.18 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $74.34B | $6.52B |
Dividend Yield | 2.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
State Street (STT) trades at $173.99, down 0.54% with bearish technical signals despite strong Q3 2026 earnings beat. The stock faces headwinds from a revenue miss and ongoing investigation, though fundamentals show robust profitability with 22.95% net margin and consistent earnings growth. Analyst consensus remains positive with $183.55 price target, but technical indicators show selling pressure with support at $172.
Outlook is mixed with strong fundamentals supporting long-term value, but near-term risks from the securities investigation and bearish technicals create uncertainty. The 13% revenue growth and record AUM provide upside potential, though investors should monitor legal developments and expense trends that could impact sentiment.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street Corporation Common Stock
State Street provides investment servicing, custody, and asset management services to institutional investors. Its asset management business includes the SPDR ETF range.
Read more on STT →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
